key: cord-0907714-s1mym0kq
authors: Kosugi, Eduardo Macoto; Lavinsky, Joel; Romano, Fabrizio Ricci; Fornazieri, Marco Aurélio; Luz-Matsumoto, Gabriela Ricci; Lessa, Marcus Miranda; Piltcher, Otavio; Sant’Anna, Geraldo Druck
title: Incomplete and late recovery of sudden olfactory dysfunction in COVID-19()
date: 2020-05-25
journal: Braz J Otorhinolaryngol
DOI: 10.1016/j.bjorl.2020.05.001
sha: 078ae63961e3c3f403a6a4d30c6a918fedab5f16
doc_id: 907714
cord_uid: s1mym0kq

INTRODUCTION: Sudden olfactory dysfunction is a new symptom related to COVID-19, with little data on its duration or recovery rate. OBJECTIVE: To characterize patients with sudden olfactory disfunction during the COVID-19 pandemic, especially their recovery data. METHODS: An online survey was conducted by the Brazilian Society of Otorhinolaryngology and Cervico-Facial Surgery, and Brazilian Academy of Rhinology, including doctors who assessed sudden olfactory dysfunction patients starting after February 1(st), 2020. RESULTS: 253 sudden olfactory dysfunction patients were included, of which 59.1% were females with median age of 36 years, with a median follow-up period of 31 days. 183 patients (72.3%) had been tested for COVID-19, and of those 145 (79.2%) tested positive. Patients that tested positive for COVID-19 more frequently showed non-specific inflammatory symptoms (89.7% vs. 73.7%; p = 0.02), a lower rate of total recovery of sudden olfactory dysfunction (52.6% vs. 70.3%; p = 0.05) and a longer duration to achieve total recovery (15 days vs. 10 days; p = 0.0006) than the ones who tested negative for COVID-19. Considering only positive-COVID-19 patients, individuals with sudden hyposmia completely recovered more often than the ones with sudden anosmia (68.4% vs. 50.0%; p = 0.04). CONCLUSION: Positive-COVID-19 patients with sudden olfactory dysfunction showed lower total recovery rate and longer duration than negative-COVID-19 patients. Additionally, total recovery was seen more frequently in positive-COVID-19 patients with sudden hyposmia than the ones with sudden anosmia.

7> < colspeccolname =col1/ >< colspeccolname =col2/ >< colspeccolname =col3/ >< colspeccolname =col4/ >< colspeccolname =col5/ >< colspeccolname =col6/ >< colspeccolname =col7/ >< theadvalign =ẗop> < row >< entrynamest =col1nameend = col2rowsep =1älign =left>Characteristicsoftestedpatients(n < ce : hspsp =0.25/ > = < ce : hspsp =0.25/ > 183) < /entry >< entrynamest =col3nameend =col6rowsep =1älign = left>COVID − 19test < /entry >< entry/ >< /row >< row >< entryrowsep =1/ >< entryrowsep =1/ >< entrynamest =col3nameend =col4rowsep =1älign =left>Positive(n < ce : hspsp =0.25/ > = < ce : hspsp =0.25/ > 145) < /entry >< entrynamest = col5nameend =col6rowsep =1älign =left>Negative(n < ce : hspsp =0.25/ > = < ce : hspsp =0.25/ > 38) < /entry >< entryrowsep =1älign =left>p−value < /entry >< /row >< /thead >< tbody >< row >< entryalign =leftrole =rowhead>Age(years) < /entry >< entryalign =left>MedandIQR < /entry >< entryalign =left>36 < /entry >< entryalign =left>31-44 < /entry >< entryalign =left>35.5 < /entry >< entryalign = left>30.25-45.25 < /entry >< entryalign =left>0.60 < /entry >< /row >< row >< entryalign =leftrole =rowhead>Follow − up(days) < /entry >< entryalign = left>MedandIQR < /entry >< entryalign =left>31 < /entry >< entryalign =left>12-39 < /entry >< entryalign =left>35.5 < /entry >< entryalign =left>17-41 < /entry >< entryalign =left>0.37 < /entry >< /row >< row >< entryalign =leftrole = rowhead>Femalegender < /entry >< entryalign =left>ne% < /entry >< entryalign = left>77 < /entry >< entryalign =left>53.1 < /entry >< entryalign =left>26 < /entry >< entryalign =left>68.4 < /entry >< entryalign =left>0.10 < /entry >< /row >< row >< entryalign =leftrole =rowhead>AcuteAnosmia < /entry >< entryalign =left>ne% < /entry >< entryalign =left>126 < /entry >< entryalign =left>86.9 < /entry >< entryalign =left>31 < /entry >< entryalign =left>81.6 < /entry >< entryalign = left>0.44 < /entry >< /row >< row >< entryalign =leftrole =rowhead>AcuteHyposmia < /entry >< entryalign =left>ne% < /entry >< entryalign =left>19 < /entry >< entryalign = left>13.1 < /entry >< entryalign =left>7 < /entry >< entryalign =left>18.4 < /entry >< entryalign =left>0.44 < /entry >< /row >< row >< entryalign =leftrole = rowhead>Comorbidities < /entry >< entryalign =left>ne% < /entry >< entryalign = left>47 < /entry >< entryalign =left>32.4 < /entry >< entryalign =left>15 < /entry >< entryalign =left>39.5 < /entry >< entryalign =left>0.44 < /entry >< /row >< row >< entryalign =leftrole =rowhead>AllergicRhinitis < /entry >< entryalign =left>ne% < /entry >< entryalign =left>22 < /entry >< entryalign =left>15.2 < /entry >< entryalign = left>8 < /entry >< entryalign =left>21.1 < /entry >< entryalign =left>0.46 < /entry >< /row >< row >< entryalign =leftrole =rowhead>Asthma < /entry >< entryalign = left>ne% < /entry >< entryalign =left>7 < /entry >< entryalign =left>4.8 < /entry >< entryalign =left>0 < /entry >< entryalign =left>0.0 < /entry >< entryalign =left>0.35 < /entry >< /row >< /tbody >< /tgroup >< ce : legend >< ce : simple − paraid = spar0065>n, Number; Med, Median; IQR, InterquartileRange; %, Percentage. < /ce : simple − para >< /ce : legend >< /ce : table >< ce : tableid =ẗbl0010f rame = topbotrowsep =0colsep =0> < ce : label > Table2 < /ce : label >< ce : captionid = cap0015> < ce : simple − paraid =spar0070>SymptomsofpatientstestedforCOVID − 19. < /ce : simple − para >< /ce : caption >< ce : alt − textid =ät2role =short>Table2 < /ce : alt − text >< tgroupcols =6> < colspeccolname =col1/ >< colspeccolname =col2/ >< colspeccolname =col3/ >< colspeccolname =col4/ >< colspeccolname =col5/ >< colspeccolname =col6/ >< theadvalign =ẗop> < row >< entryalign =leftrole = rowhead>Symptomsoftestedpatients < ce : br/ > (n < ce : hspsp =0.25/ > = < ce : hspsp = 0.25/ > 183) < /entry >< entrynamest =col2nameend =col5rowsep =1älign = left>COVID − 19Test < /entry >< entryalign =left>p−value < /entry >< /row >< row >< entryrowsep =1/ >< entrynamest =col2nameend =col3rowsep =1älign =left>Positive < ce : br/ > (n < ce : hspsp =0.25/ > = < ce : hspsp =0.25/ > 145) < /entry >< entrynamest =col4nameend =col5rowsep =1älign =left>Negative < ce : br/ > (n < ce : hspsp =0.25/ > = < ce : hspsp =0.25/ > 38) < /entry >< entryrowsep =1/ >< /row >< /thead >< tbody >< row >< entry/ >< entryalign =left>n < /entry >< entryalign = left>% < /entry >< entryalign =left>n < /entry >< entryalign =left>% < /entry >< entry/ >< /row >< row >< entryalign =leftrole =rowhead>None < /entry >< entryalign = left>8 < /entry >< entryalign =left>5.5 < /entry >< entryalign =left>5 < /entry >< entryalign =left>13.1 < /entry >< entryalign =left>0.15 < /entry >< /row >< row >< entryalign =leftrole =rowhead>Nonspecificsymptoms < /entry >< entryalign =left>130 < /entry >< entryalign =left>89.7 < /entry >< entryalign =left>28 < /entry >< entryalign = left>73.7 < /entry >< entryalign =left>0.02 < ce : cross − refid =crf 0005refid = tblfn0005> a </ce:cross-ref></entry></row><row><entry align=leftrole=rowhead>Coughing</entry><entry align=left>83</entry><entry align=left>57.2</entry><entry align=left>18</entry><entry align=left>47.3</entry><entry align=left>0.36</entry></row><row><entry align=leftrole=rowhead>Headache</entry><entry align=left>76</entry><entry align=left>52.4</entry><entry align=left>20</entry><entry align=left>52.6</entry><entry align=left>1.00</entry></row><row><entry align=leftrole=rowhead>Fever</entry><entry align=left>72</entry><entry align=left>49.7</entry><entry align=left>16</entry><entry align=left>42.1</entry><entry align=left>0.47</entry></row><row><entry align=leftrole=rowhead>Myalgia/arthralgia</entry><entry align=left>37</entry><entry align=left>25.5</entry><entry align=left>8</entry><entry align=left>21.0</entry><entry align=left>0.68</entry></row><row><entry align=leftrole=rowhead>Fatigue</entry><entry align=left>20</entry><entry align=left>13.7</entry><entry align=left>7</entry><entry align=left>18.4</entry><entry align=left>0.14</entry></row><row><entry align=leftrole=rowhead>Anorexia</entry><entry align=left>4</entry><entry align=left>2.7</entry><entry align=left>2</entry><entry align=left>5.2</entry><entry align=left>0.61</entry></row><row><entry align=leftrole=rowhead>Nasal Symptoms</entry><entry align=left>62</entry><entry align=left>42.7</entry><entry align=left>15</entry><entry align=left>39.4</entry><entry align=left>0.85</entry></row><row><entry align=leftrole=rowhead>Nasal Obstruction</entry><entry align=left>40</entry><entry align=left>27.5</entry><entry align=left>8</entry><entry align=left>21.0</entry><entry align=left>0.54</entry></row><row><entry align=leftrole=rowhead>Sneezing</entry><entry align=left>18</entry><entry align=left>12.4</entry><entry align=left>4</entry><entry align=left>10.5</entry><entry align=left>1.00</entry></row><row><entry align=leftrole=rowhead>Coryza</entry><entry align=left>31</entry><entry align=left>21.3</entry><entry align=left>8</entry><entry align=left>21.0</entry><entry align=left>1.00</entry></row><row><entry align=leftrole=rowhead>Rhinorrhea</entry><entry align=left>2</entry><entry align=left>1.3</entry><entry align=left>1</entry><entry align=left>2.6</entry><entry align=left>0.51</entry></row><row><entry align=leftrole=rowhead>Nasal Pruritus</entry><entry align=left>6</entry><entry align=left>4.1</entry><entry align=left>2</entry><entry align=left>5.2</entry><entry align=left>0.67</entry></row><row><entry align=leftrole=rowhead>URTIs (nose and/or throat)</entry><entry align=left>66</entry><entry align=left>45.5</entry><entry align=left>16</entry><entry align=left>42.1</entry><entry align=left>0.86</entry></row><row><entry align=leftrole=rowhead>Sore throat</entry><entry align=left>10</entry><entry align=left>6.9</entry><entry align=left>4</entry><entry align=left>10.5</entry><entry align=left>0.56</entry></row><row><entry align=leftrole=rowhead>Others</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry align=leftrole=rowhead>Dyspnea</entry><entry align=left>7</entry><entry align=left>4.8</entry><entry align=left>2</entry><entry align=left>5.2</entry><entry align=left>1.00</entry></row><row><entry align=leftrole=rowhead>Diarrhea</entry><entry align=left>10</entry><entry align=left>6.9</entry><entry align=left>1</entry><entry align=left>2.6</entry><entry align=left>0.46</entry></row><row><entry align=leftrole=rowhead>Ageusia</entry><entry align=left>6</entry><entry align=left>4.1</entry><entry align=left>2</entry><entry align=left>5.2</entry><entry align=left>0.67</entry></row></tbody></tgroup><ce:legend><ce:simple-para id=spar0075>n, Number; %, Percentage.</ce:simple-para></ce:legend><ce:table-footnote id=ẗblfn0005><ce:label>a</ce:label><ce:note-para id=npar0005>Statistical Significance.</ce:note-para></ce:table-footnote></ce:table><ce:table id=ẗbl0015frame=ẗopbotrowsep=0colsep=0><ce:label>Table 3</ce:label><ce:caption id=cap0020><ce:simple-para id=spar0080>Recovery from loss of olfaction in patients tested for COVID-19.</ce:simple-para></ce:caption><ce:alt-text id=ät3role=short>Table 3</ce:alt-text><tgroup cols=7><colspec colname=col1/><colspec colname=col2/><colspec colname=col3/><colspec colname=col4/><colspec colname=col5/><colspec colname=col6/><colspec colname=col7/><thead valign=ẗop><row><entry namest=col1nameend=col2rowsep=1älign=left>Recovery from sudden olfactory dysfunction (n<ce:hsp sp=0.25/>=<ce:hsp sp=0.25/>174)</entry><entry namest=col3nameend=col6rowsep=1älign=left>COVID-19 Test</entry><entry align=left>p-value</entry></row><row><entry rowsep=1/><entry rowsep=1/><entry namest=col3nameend=col4rowsep=1älign=left>Positive (n<ce:hsp sp=0.25/>=<ce:hsp sp=0.25/>137)</entry><entry namest=col5nameend=col6rowsep=1älign=left>Negative (n<ce:hsp sp=0.25/>=<ce:hsp sp=0.25/>37)</entry><entry rowsep=1/></row></thead><tbody><row><entry align=leftrole=rowhead>Full recovery</entry><entry align=left>n and %</entry><entry align=left>72</entry><entry align=left>52.6</entry><entry align=left>26</entry><entry align=left>70.3</entry><entry align=left>0.05<ce:cross-ref id=crf0010refid=ẗblfn0010> a </ce:cross-ref></entry></row><row><entry align=leftrole=rowhead>Partial recovery</entry><entry align=left>n and %</entry><entry align=left>46</entry><entry align=left>33.6</entry><entry align=left>10</entry><entry align=left>27.0</entry><entry/></row><row><entry align=leftrole=rowhead>No recovery</entry><entry align=left>n and %</entry><entry align=left>19</entry><entry align=left>13.9</entry><entry align=left>1</entry><entry align=left>2.7</entry><entry/></row><row><entry align=leftrole=rowhead>Time to full recovery</entry><entry align=left>Med and IQR</entry><entry align=left>15</entry><entry align=left>10-21</entry><entry align=left>10</entry><entry align=left>8-12.75</entry><entry align=left>0.0006<ce:cross-ref id=crf0015refid=ẗblfn0010> a </ce:cross-ref></entry></row></tbody></tgroup><ce:legend><ce:simple-para id=spar0085>n, Number; %, Percentage; Med, Median; IQR, Interquartile Range.</ce:simple-para></ce:legend><ce:table-footnote id=ẗblfn0010><ce:label>a</ce:label><ce:note-para id=npar0010>Statistical significance.</ce:note-para></ce:table-footnote></ce:table><ce:table id=ẗbl0020frame=ẗopbotrowsep=0colsep=0><ce:label>Table 4</ce:label><ce:caption id=cap0025><ce:simple-para id=spar0090>Recovery from acute anosmia and hyposmia in positive-COVID-19 patients.</ce:simple-para></ce:caption><ce:alt-text id=ät4role=short>Table 4</ce:alt-text><tgroup cols=7><colspec colname=col1/><colspec colname=col2/><colspec colname=col3/><colspec colname=col4/><colspec colname=col5/><colspec colname=col6/><colspec colname=col7/><thead valign=ẗop><row><entry namest=col1nameend=col2rowsep=1älign=left>Recovery from sudden olfactory dysfunction (n<ce:hsp sp=0.25/>=<ce:hsp sp=0.25/>137)</entry><entry namest=col3nameend=col6rowsep=1älign=left>Positive-COVID-19</entry><entry align=left>p-value</entry></row><row><entry rowsep=1/><entry rowsep=1/><entry namest=col3nameend=col4rowsep=1älign=left>Anosmia (n<ce:hsp sp=0.25/>=<ce:hsp sp=0.25/>118)</entry><entry namest=col5nameend=col6rowsep=1älign=left>Hyposmia (n<ce:hsp sp=0.25/>=<ce:hsp sp=0.25/>19)</entry><entry rowsep=1/></row></thead><tbody><row><entry align=leftrole=rowhead>Full recovery</entry><entry align=left>n and %</entry><entry align=left>59</entry><entry align=left>50.0</entry><entry align=left>13</entry><entry align=left>68.4</entry><entry/></row><row><entry align=leftrole=rowhead>Partial recovery</entry><entry align=left>n and %</entry><entry align=left>44</entry><entry align=left>37.3</entry><entry align=left>2</entry><entry align=left>10.5</entry><entry align=left>0.04<ce:cross-ref id=crf0020refid=ẗblfn0015> a </ce:cross-ref></entry></row><row><entry align=leftrole=rowhead>No recovery</entry><entry align=left>n and %</entry><entry align=left>15</entry><entry align=left>12.7</entry><entry align=left>4</entry><entry align=left>21.1</entry><entry/></row><row><entry align=leftrole=rowhead>Time to full recovery</entry><entry align=left>Med and IQR</entry><entry align=left>15.5</entry><entry align=left>10.75-23</entry><entry align=left>11</entry><entry align=left>9-16</entry><entry align=left>0.10</entry></row></tbody></tgroup><ce:legend><ce:simple-para id=spar0095>n, Number; %, Percentage; Med, Median; IQR, Interquartile Range.</ce:simple-para></ce:legend><ce:table-footnote id=ẗblfn0015><ce:label>a</ce:label><ce:note-para id=npar0015>Statistical significance.</ce:note-para></ce:table-footnote></ce:table></ce:floats><head><ce:article-footnote><ce:label>ଝ</ce:label><ce:note-para id=npar0020>Please cite this article as: Kosugi EM, Lavinsky J, Romano FR, Fornazieri MA, Luz-Matsumoto GR, Lessa MM, et al. Recuperação incompleta e tardia da perda súbita do olfato na COVID-19. <ce:inter-ref id=ïntr0005ẍlink:href=ḧttps://doi.org/10.1016/j.bjorl.2020.05.001>https://doi.org/10.1016/j.bjorl.2020.05.001</ce:inter-ref></ce:note-para></ce:article-footnote><ce:article-footnote><ce:note-para id=npar0025>Peer Review under the responsibility of Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.</ce:note-para></ce:article-footnote><ce:dochead id=doh0005><ce:textfn>Original Article</ce:textfn></ce:dochead><ce:title id=ẗit0005>Incomplete and late recovery of sudden olfactory dysfunction in COVID-19<!-<query id=Q1>Please check the short title that has been created, or suggest an alternative of fewer than 80 characters including spaces.</query>-><!-<RunningTitle>Incomplete and late recovery of sudden olfactory dysfunction in COVID-19</RunningTitle>-></ce:title><ce:alt-title xml:lang=ës>Recuperação incompleta e tardia da perda súbita do olfato na COVID-19</ce:alt-title><ce:author-group id=äug0005><ce:author id=äut0005örcid=0000-0003-1318-0541äuthor-id=S1808869420300598-a5db1aeba94185125ce85f57ee13bc7e><ce:given-name>Eduardo Macoto</ce:given-name><ce:surname>Kosugi<!-<query id=Q2>Please confirm that given name and surname are correctly identified. The different colors indicate whether tagged as first or last name. Please note that proper identification is key for correct indexing of the article.</query>-></ce:surname> <ce:cross-ref id=crf0025refid=äff0005> a </ce:cross-ref><ce:cross-ref id=crf0030refid=äff0010> b </ce:cross-ref><ce:cross-ref id=crf0035refid=cor0005> x204E </ce:cross-ref><ce:e-address id=ëadd0005ẗype=ëmailẍlink:href=mailto:edumacoto@gmail.com>edumacoto@gmail.com</ce:e-address></ce:author><ce:author id=äut0010örcid=0000-0002-0377-5704äuthor-id=S1808869420300598-869df97ebdbccd071dd6b31c01856316><ce:given-name>Joel</ce:given-name><ce:surname>Lavinsky</ce:surname> <ce:cross-ref id=crf0040refid=äff0010> b </ce:cross-ref></ce:author><ce:author id=äut0015örcid=0000-0002-2218-8417äuthor-id=S1808869420300598-0f1df3fd7506e12df0a91e0f75d1a55d><ce:given-name>Fabrizio Ricci</ce:given-name><ce:surname>Romano</ce:surname> <ce:cross-ref id=crf0045refid=äff0005> a </ce:cross-ref><ce:cross-ref id=crf0050refid=äff0010> b </ce:cross-ref></ce:author><ce:author id=äut0020örcid=0000-0001-5213-2337äuthor-id=S1808869420300598-0f2fa2d50d2ffd702eeedc3807387253><ce:given-name>Marco Aurélio</ce:given-name><ce:surname>Fornazieri</ce:surname> <ce:cross-ref id=crf0055refid=äff0005> a </ce:cross-ref></ce:author><ce:author id=äut0025örcid=0000-0003-0793-153Xäuthor-id=S1808869420300598-b19b81f7c163440b5c9aeade2a33457a><ce:given-name>Gabriela Ricci</ce:given-name><ce:surname>Luz-Matsumoto</ce:surname> <ce:cross-ref id=crf0060refid=äff0005> a </ce:cross-ref></ce:author><ce:author id=äut0030örcid=0000-0002-5003-0828äuthor-id=S1808869420300598-c33aa14942b78a115102bfb76d2a4cbd><ce:given-name>Marcus Miranda</ce:given-name><ce:surname>Lessa</ce:surname> <ce:cross-ref id=crf0065refid=äff0005> a </ce:cross-ref></ce:author><ce:author id=äut0035örcid=0000-0003-3384-3664äuthor-id=S1808869420300598-384591332b69a0bea08be91499e68878><ce:given-name>Otavio</ce:given-name><ce:surname>Piltcher</ce:surname> <ce:cross-ref id=crf0070refid=äff0005> a </ce:cross-ref></ce:author><ce:author id=äut0040örcid=0000-0002-5130-2776äuthor-id=S1808869420300598-4add13faf200fbfce85f2b64e7cb6716><ce:given-name>Geraldo Druck</ce:given-name><ce:surname>Sant'Anna</ce:surname> <ce:cross-ref id=crf0075refid=äff0010> b </ce:cross-ref></ce:author><ce:affiliation id=äff0005äffiliation-id=S1808869420300598-0b2db4acc4c20cebc033007756bd750c><ce:label>a</ce:label><ce:textfn>Academia Brasileira de Rinologia (ABR), <!-<city>->São Paulo<!-</city>->, <!-<state>->SP<!-</state>->, <!-<country>->Brazil<!-</country>-></ce:textfn><sa:affiliation><sa:organization>Academia Brasileira de Rinologia (ABR)</sa:organization><sa:city>São Paulo</sa:city><sa:state>SP</sa:state><sa:country>Brazil</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id=äff0010äffiliation-id=S1808869420300598-c3bd325984cda11d84f9772f12d98fd0><ce:label>b</ce:label><ce:textfn>Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF), <!-<city>->São Paulo<!-</city>->, <!-<state>->SP<!-</state>->, <!-<country>->Brazil<!-</country>-></ce:textfn><sa:affiliation><sa:organization>Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)</sa:organization><sa:city>São Paulo</sa:city><sa:state>SP</sa:state><sa:country>Brazil</sa:country></sa:affiliation></ce:affiliation><ce:correspon id=cor0005><ce:label>*</ce:label><ce:text>Corresponding author.</ce:text></ce:correspondence></ce:author-group><ce:date-received day=8month=5ÿear=2020/><ce:date-accepted day=11month=5ÿear=2020/><ce:abstract id=äbs0010><ce:section-title id=sect0005>Abstract</ce:section-title><ce:abstract-sec id=äbst0005role=ïntroduction><ce:section-title id=sect0010>Introduction</ce:section-title><ce:simple-para id=spar0005>Sudden olfactory dysfunction is a new symptom related to COVID-19, with little data on its duration or recovery rate.</ce:simple-para></ce:abstract-sec><ce:abstract-sec id=äbst0010><ce:section-title id=sect0015>Objective</ce:section-title><ce:simple-para id=spar0010>To characterize patients with sudden olfactory disfunction during the COVID-19 pandemic, especially their recovery data.</ce:simple-para></ce:abstract-sec><ce:abstract-sec id=äbst0015><ce:section-title id=sect0020>Methods</ce:section-title><ce:simple-para id=spar0015>An online survey was conducted by the Brazilian Society of Otorhinolaryngology and Cervico-Facial Surgery, and Brazilian Academy of Rhinology, including doctors who assessed sudden olfactory dysfunction patients starting after February 1 st , 2020.</ce:simple-para></ce:abstract-sec><ce:abstract-sec id=äbst0020role=results><ce:section-title id=sect0025>Results</ce:section-title><ce:simple-para id=spar0020>253 sudden olfactory dysfunction patients were included, of which 59.1% were females with median age of 36 years, with a median follow-up period of 31 days. 183 patients (72.3%) had been tested for COVID-19, and of those 145 (79.2%) tested positive. Patients that tested positive for COVID-19 more frequently showed non-specific inflammatory symptoms (89.7% vs. 73.7%; p<ce:hsp sp=0.25/>=<ce:hsp sp=0.25/>0.02), a lower rate of total recovery of sudden olfactory dysfunction (52.6% vs. 70.3%; p<ce:hsp sp=0.25/>=<ce:hsp sp=0.25/>0.05) and a longer duration to achieve total recovery (15 days vs. 10 days; p<ce:hsp sp=0.25/>=<ce:hsp sp=0.25/>0.0006) than the ones who tested negative for COVID-19. Considering only positive-COVID-19 patients, individuals with sudden hyposmia completely recovered more often than the ones with sudden anosmia (68.4% vs. 50.0%; p<ce:hsp sp=0.25/>=<ce:hsp sp=0.25/>0.04).</ce:simple-para></ce:abstract-sec><ce:abstract-sec id=äbst0025role=conclusion><ce:section-title id=sect0030>Conclusion</ce:section-title><ce:simple-para id=spar0025>Positive-COVID-19 patients with sudden olfactory dysfunction showed lower total recovery rate and longer duration than negative-COVID-19 patients. Additionally, total recovery was seen more frequently in positive-COVID-19 patients with sudden hyposmia than the ones with sudden anosmia.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract id=äbs0005ẍml:lang=pt><ce:section-title id=sect0035>Resumo</ce:section-title><ce:abstract-sec id=äbst0030><ce:section-title id=sect0040>Introduccedil;atilde;o</ce:section-title><ce:simple-para id=spar0030>A perda suacute;bita do olfato eacute; um novo sintoma relacionado agrave; COVID-19, poreacute;m com poucos dados sobre sua duraccedil;atilde;o ou resoluccedil;atilde;o.</ce:simple-para></ce:abstract-sec><ce:abstract-sec id=äbst0035><ce:section-title id=sect0045>Objetivo</ce:section-title><ce:simple-para id=spar0035>Caracterizar pacientes que apresentaram perda suacute;bita do olfato durante a pandemia da COVID-19, e em especial a sua recuperaccedil;atilde;o.</ce:simple-para></ce:abstract-sec><ce:abstract-sec id=äbst0040><ce:section-title id=sect0050>Meacute;todo</ce:section-title><ce:simple-para id=spar0040>Pesquisa online desenvolvida pela Associaccedil;atilde;o Brasileira de Otorrinolaringologia e Cirurgia Ceacute;rvico-Facial e Academia Brasileira de Rinologia direcionado aos meacute;dicos que atenderam pacientes com perda suacute;bita do olfato com iniacute;cio apoacute;s 01 de fevereiro de 2020.</ce:simple-para></ce:abstract-sec><ce:abstract-sec id=äbst0045><ce:section-title id=sect0055>Resultados</ce:section-title><ce:simple-para id=spar0045>Foram incluiacute;dos 253 pacientes com perda suacute;bita de olfato, sendo 59,1% mulheres e idade mediana de 36 anos, acompanhados por 31 dias (mediana >0,04) .</ce:simple-para></ce:abstract-sec><ce:abstract-sec id=äbst0050><ce:section-title id=sect0060>Conclusatilde;o</ce:section-title><ce:simple-para id=spar0050>A perda suacute;bita do olfato em pacientes COVID-19 positivos apresentou menor taxa de recuperaccedil;atilde;o total e duraccedil;atilde;o mais prolongada do que em COVID-19 negativos. E a hiposmia suacute;bita apresentou recuperaccedil;atilde;o total mais frequentemente que a anosmia suacute;bita em COVID-19 positivos.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords id=kwd0005class=keyword><ce:section-title id=sect0065>Keywords</ce:section-title><ce:keyword id=kw0005><ce:text>COVID-19</ce:text></ce:keyword><ce:keyword id=kw0010><ce:text>Anosmia</ce:text></ce:keyword><ce:keyword id=kw0015><ce:text>Olfactory disorders</ce:text></ce:keyword></ce:keywords><ce:keywords id=kwd0010class=keywordẍml:lang=pt><ce:section-title id=sect0070>Palavras-chave</ce:section-title><ce:keyword id=kw0020><ce:text>COVID-19</ce:text></ce:keyword><ce:keyword id=kw0025><ce:text>Anosmia</ce:text></ce:keyword><ce:keyword id=kw0030><ce:text>Transtornos do olfato</ce:text></ce:keyword></ce:keywords></head><body><ce:sections><ce:section id=sec0005role=ïntroduction><ce:section-title id=sect0075>Introduction</ce:section-title><ce:para id=par0005><!-<ForCovergt; This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Objective: To characterize patients with sudden olfactory disfunction during the COVID-19 pandemic, especially their recovery data.

Otorhinolaryngology and Cervico-Facial Surgery, and Brazilian Academy of Rhinology , including doctors who assessed sudden olfactory dysfunction patients starting after Conclusion: Positive-COVID-19 patients with sudden olfactory dysfunction showed lower total recovery rate and longer duration than negative-COVID-19 patients.

Additionally, total recovery was seen more frequently in positive-COVID-19 patients with sudden hyposmia than the ones with sudden anosmia.

Anosmia;

Introdução: A perda súbita do olfato é um novo sintoma relacionado à COVID-19, porém com poucos dados sobre sua duração ou resolução.

Objetivo: Caracterizar pacientes que apresentaram perda súbita do olfato durante a pandemia da COVID-19, e em especial a sua recuperação. negativos. E a hiposmia súbita apresentou recuperação total mais frequentemente que a anosmia súbita em COVID-19 positivos.

Human Coronaviruses (HCoVs) were first identified in the nasal cavities of patients with the common cold in the 1960s, [1] being responsible for 10% to 15% of these cases, second only to rhinoviruses. [2] Although most cases of HCoV infection show symptoms compatible with the common cold or mild flu-like syndromes, the lower respiratory tract can be severely affected, as in outbreaks caused by the SARS-CoV, MERS-CoV species, and now with the new coronavirus (SARS-COV-2), which causes the COVID-19 disease. [1] In China, the analysis of 72,314 cases up to February 11, 2020 showed that 14% of patients with COVID-19 had severe disease and 5% were critically ill, leading to a case fatality rate of 2.3%. [3] In Brazil, at the beginning of May 2020, there were already more than 145,000 confirmed cases, with a case fatality rate reaching 6.8%. [4] In addition to respiratory symptoms, an unusual finding started to be noticed in patients with COVID-19: sudden anosmia. A study focusing on neurological alterations showed only 5.1% of changes in smell in patients hospitalized with COVID-19 in J o u r n a l P r e -p r o o f Wuhan, China, [5] compatible with a prevalence of 5.8% of anosmia in population studies. [6] However, in Europe, 85.6% of patients with mild to moderate COVID-19 had a sudden change in olfaction, with 79.6% anosmia and 20.4% hyposmia. [7] This finding did not seem to follow the usual pattern of post-viral olfaction alterations: in the USA, a study comparing patients with flu-like symptoms showed a 16% prevalence of post-viral olfaction alteration, which increased to 68% in positive-COVID-19 patients, [8] similar to the European and in disagreement with the Chinese data.

Interestingly, in the first study using olfactory tests in these patients, carried out in Iran, the prevalence of olfactory dysfunction assessed in those infected with SARS-CoV-2 reached 98%. [9] The reports of sudden anosmia by COVID-19 led the Brazilian Academy of if there was a test to confirm COVID-19, and the result of this test. The survey was distributed digitally by ABORL-CCF via its website (www.aborlccf.org.br), Whatsapp ® and Instagram ® . Data were collected between March 25 and April 30, 2020. The participating physicians were asked for authorization to use the included data. Data on the recovery from sudden anosmia or hyposmia and test for COVID-19 were confirmed via e-mail, and information on the time for total recovery from anosmia or hyposmia and how long the patient was followed by the doctor were also collected. Symptom prevalence rates were described in percentages, whereas continuous variables, such as duration of complaints and age, were described in medians and Interquartile Range (IQR). Proportions were compared using Fisher's exact or Chisquare test. The difference in age distribution, time to total recovery and duration of patient follow-up were calculated using the Mann-Whitney U test due to the non-normal distribution of data calculated by the Kolmogorov-Smirnov test. The level of significance was set at 5% and the tests used were two-tailed.

A total of 253 patients was included, treated in all regions of Brazil, distributed as follows: 142 (56.1%) in the Southeast, 59 (23.3%) in the Northeast, 32 (12.6%) in the South, 10 (4.0%) in the North and 10 (4.0%) in the Midwest. There was a predominance of women (149 patients -58.9%), and the median age was 36 years (IQR 30-44 years).

Most patients had sudden anosmia (212 patients -83.8%) instead of sudden hyposmia, and in most cases (196 patients -77.5%), loss of smell was accompanied by nonspecific inflammatory symptoms (coughing, fever, headache, fatigue/malaise, myalgia/arthralgia and/or anorexia). Nasal symptoms (nasal obstruction, sneezing, coryza, purulent rhinorrhea, nasal pruritus and / or nasal burning) were reported by 111 patients (43.9%) and sore throat by 16 (6.3%). Only 36.4% of the patients reported comorbidities, with rhinitis being the most frequent one (53 patients -20.9%), followed by asthma and systemic arterial hypertension (SAH), with 13 patients each (5.1%). patients. There were no differences regarding epidemiological characteristics between positive-and negative-COVID-19 patients, as shown in Table 1 .

Positive-COVID-19 patients more commonly had nonspecific inflammatory symptoms (coughing, fever, headache, fatigue/malaise, myalgia/arthralgia and/or anorexia) than negative-COVID-19 ones (89.7% vs. 73.7 %; p = 0.02*). There were no statistically significant differences between the two groups for the other symptoms, as shown in Table 2 . There were also no differences regarding the patterns of treatment used in the two groups of patients.

Sudden olfactory dysfunction in the positive-COVID-19 patients showed a lower full recovery rate (Fig. 1) and a longer duration than in the negative-COVID-19 ones (Table 3) When analyzing only positive-COVID-19 patients, it was observed that those with hyposmia recovered more easily than the ones with anosmia (Table 4) ; there was J o u r n a l P r e -p r o o f no difference in the full recovery from sudden olfactory dysfunction due to the different treatments used; and that there was no association between full recovery from sudden olfactory dysfunction due to the presence or absence of other symptoms.

This is the first Brazilian study to assess sudden olfactory dysfunction in the context of the COVID-19 pandemic. The most relevant finding in the present study was the demonstration that the sudden olfactory dysfunction associated with COVID-19 had a lower rate of full recovery and a longer duration than in negative-COVID-19 patients.

Only half of the positive-COVID-19 patients fully recovered olfaction, compared to 70.3% of the negative-COVID-19 ones (p = 0.05). Considering only those who fully recovered the olfaction, it took positive-COVID-19 patients 15 days (median) to fully recover their sense of smell, 5 days longer than negative-COVID-19 ones (p = 0.0006).

The second relevant point is that the full recovery from sudden hyposmia in positive-COVID-19 patients occurred more frequently than that from sudden anosmia (p = 0.04).

Women have complained more about loss of olfaction during the COVID-19 pandemic, representing up to three quarters of the cases, [11] which, however, is reduced to two-thirds when there is diagnostic confirmation of COVID-19. [7] The present research included a total of 59.1% of women with olfactory dysfunction, being 53.1% when positive-COVID-19 cases were confirmed. However, it is interesting to mention that population studies tend to show a higher prevalence of olfactory dysfunction in men. [6] This skewed distribution of loss of smell in COVID-19 may be due to the decreased capacity of men to perceive the olfactory dysfunction, or even women's greater concern for their health, or an actual selectivity of SARS-CoV-2 for the female gender.

Another discrepant point between the olfactory dysfunction related to COVID-19 and that found in the general population is the anosmia /hyposmia ratio. The prevalence of hyposmia is usually more than two-fold that of anosmia, [6] but the studies by Hopkins et al. [11] and Lechien et al. [7] showed that 74.4 and 76.9% of the olfactory dysfunction cases related to COVID-19 were those of anosmia, not hyposmia.

In agreement with that, 83.4% of olfaction complaints in the present study were of anosmia, reaching 86.9% in positive-COVID-19 patients.

Although HCoVs are the second most frequent cause of acute nasopharyngitis, [2] SARS-CoV-2 does not seem to predominantly promote nasal or J o u r n a l P r e -p r o o f pharyngeal conditions, [7, 8, [11] [12] [13] hence, the recommendation made by the 4 th Guidance Note of ABR / ABORL-CCF was to always suspect COVID-19 in the current scenario, in cases of sudden anosmia that was not accompanied by nasal obstruction. [10] However, among the positive-COVID-19 patients in this study, 27.5% had nasal obstruction concomitantly. Therefore, we should not exclude the possibility of COVID-19 just because the patient has upper airway symptoms. Sore throat was uncommon in the present study (6.9% vs. 10.5%; p = 0.56), according to the findings of Yan et al. [8] who showed that sore throat was independently associated with negative-COVID-19 patients, with these patients being 4 to 5 times more likely to report sore throat as a symptom than the positive ones.

Nonspecific inflammatory symptoms such as coughing, headache, fever, myalgia/arthralgia and fatigue are usually the most prevalent ones in COVID-19. [7, 8, [11] [12] [13] In the present study, positive-COVID-19 patients with sudden olfactory dysfunction had more general inflammatory symptoms (with coughing, headache and fever being the most common ones) than negative-COVID-19 patients (89.7% vs.

73.7%; p = 0.02*), corroborating the supposition that SARS-CoV-2 causes predominantly nonspecific inflammatory symptoms.

Sudden olfactory dysfunction alone (with no other symptoms) is not the norm.

Hopkins et al. [11] showed that only 16% of patients had sudden olfactory dysfunction without other symptoms, consistent with our global finding of 12.1% of isolated anosmia/hyposmia in the context of the pandemic. It is worth mentioning that, among our positive-COVID-19 patients, only 5.5% had isolated sudden olfactory dysfunction.

Dyspnea was not a frequent finding in the present study, which may represent the inclusion of a profile of patients with mild to moderate disease. Moreover, the presence of sudden anosmia seems to be related to the milder forms of COVID-19, as shown by Yan et al. [13] Alterations in taste were not objectively assessed in this research, which may justify its low prevalence when compared to studies that showed high rates of ageusia associated with sudden anosmia in COVID-19 cases. [8, 13] Hopkins et al., in a study with a similar design, showed that 80.1% of the patients with sudden olfactory dysfunction had some degree of olfactory recovery one week after the research, thus showing that it is likely that the olfaction will recover well in this COVID-19 pandemic scenario. However, full recovery from sudden olfactory dysfunction was reported by only 11.5% of the patients, and only 5.3% of patients in the study were tested for COVID-19, making it difficult to extrapolate the data. [14] Our global data also showed high rates of some reported degree of olfactory recovery (86.8%) over a 31-day follow-up period (median), but this does not mean full recovery from sudden olfactory dysfunction, that is, return to the levels before the sudden loss of smell, which is desired by patients and doctors. Considering that 183 patients (72.3%) were tested for COVID-19, it was possible to compare the result of sudden loss of smell between positive-and negative-COVID-19 patients. Positive-COVID-19 patients had a lower full recovery rate from sudden olfactory dysfunction than negative-COVID-19 ones (52.6% vs. 70.3%; p = 0.05*). Moreover, positive-COVID-19 patients who managed to attain full recovery took 5 days longer than negative ones (median 15 days vs. 10 days; p = 0.0006*). Therefore, our data showed that SARS-CoV-2 infection caused a type of sudden olfactory dysfunction that was more difficult to resolve than sudden anosmia/hyposmia in negative-COVID-19 patients (which may possibly represent other post-viral olfaction losses, since in the present sample, only 13.2% of negative-COVID-19 patients did not have other associated infection symptoms). There are no data on the recovery of post-viral sudden olfactory dysfunction in the acute phase; therefore, the present study may bring new data in this sense as well. The present study also showed that sudden hyposmia in the positive-COVID-19 patients had a better evolution than those with sudden anosmia, also an unprecedented finding in the literature. Testing for COVID-19 is not the norm in outpatients in most countries, so much so that previous studies of sudden olfactory dysfunction in COVID-19 with questionnaires showed low rates of tested patients included in the studies, ranging from 3.3% to 5.3%. [11, 14] The present study involved 72.3% of patients tested for COVID-19. The untested patients had a more benign profile (younger age and fewer associated symptoms), which probably led to the shorter time of follow-up and possibly to the lack of testing, due to the difficulties experienced in the pandemic for this purpose.

The positive points of the present study were the inclusion of a large sample of patients with sudden olfactory dysfunction, with a large percentage of patients being tested for COVID-19, and with a median follow-up of one month to assess the recovery from sudden olfaction loss. The negative point lies in the purely subjective analysis of sudden anosmia or hyposmia, which is not as reliable as the psychophysical tests of olfaction evaluation. [15] On the other hand, these more sensitive tests can indicate changes in olfaction in more than 50% of individuals without olfactory complaints [16] J o u r n a l P r e -p r o o f and, ultimately, it is the subjective perception of one's sense of smell that matters to the patient.

The sudden olfactory dysfunction in positive-COVID-19 patients showed a lower total recovery rate and longer duration than in negative-COVID-19 patients. Only half of the positive-COVID-19 patients fully recovered their sense of smell, with a median time of 15 days to attain recovery. Additionally, positive-COVID-19 patients with sudden hyposmia recovered more frequently than the ones with sudden anosmia.

The authors declare no conflicts of interest. J o u r n a l P r e -p r o o f 

What's New With the Old Coronaviruses?

The common cold

Characteristics of and Important Lessons From the

COVID-19) Outbreak in China

Coronavírus Brasil

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Prevalence of olfactory dysfunction: the skövde population-based study

Olfactory and gustatory dysfunctions as a clinical presentation of mild-toforms of the coronavirus disease (COVID-19): a multicenter European study

Eur Arch Oto-Rhino-Laryngology

Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol

Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol

4 a Nota de Orientação aos médicos otorrinolaringologistas sobre o COVID-19

Selfreported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study

Self-reported olfactory loss associates with outpatient clinical course in Covid-19. Int Forum Allergy Rhinol

Early recovery following new onset anosmia during the COVID-19 pandemic -an observational cohort study

Factors associated with inaccurate self-reporting of olfactory dysfunction in older US adults

A community-based study on the prevalence of olfactory dysfunction

We would like to thank the helpful collaboration of Drs